303 related articles for article (PubMed ID: 22945372)
1. Reproducibility of functional volume and activity concentration in 18F-FDG PET/CT of liver metastases in colorectal cancer.
Heijmen L; de Geus-Oei LF; de Wilt JH; Visvikis D; Hatt M; Visser EP; Bussink J; Punt CJ; Oyen WJ; van Laarhoven HW
Eur J Nucl Med Mol Imaging; 2012 Dec; 39(12):1858-67. PubMed ID: 22945372
[TBL] [Abstract][Full Text] [Related]
2. Does a novel penalized likelihood reconstruction of 18F-FDG PET-CT improve signal-to-background in colorectal liver metastases?
Parvizi N; Franklin JM; McGowan DR; Teoh EJ; Bradley KM; Gleeson FV
Eur J Radiol; 2015 Oct; 84(10):1873-8. PubMed ID: 26163992
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer.
Liao S; Penney BC; Wroblewski K; Zhang H; Simon CA; Kampalath R; Shih MC; Shimada N; Chen S; Salgia R; Appelbaum DE; Suzuki K; Chen CT; Pu Y
Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):27-38. PubMed ID: 21946983
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
[TBL] [Abstract][Full Text] [Related]
5. Repeatability of Quantitative Whole-Body 18F-FDG PET/CT Uptake Measures as Function of Uptake Interval and Lesion Selection in Non-Small Cell Lung Cancer Patients.
Kramer GM; Frings V; Hoetjes N; Hoekstra OS; Smit EF; de Langen AJ; Boellaard R
J Nucl Med; 2016 Sep; 57(9):1343-9. PubMed ID: 27103020
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of preoperative metabolic tumor volume and total lesion glycolysis measured by 18F-FDG PET/CT in salivary gland carcinomas.
Ryu IS; Kim JS; Roh JL; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
J Nucl Med; 2013 Jul; 54(7):1032-8. PubMed ID: 23670902
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of 18F-FDG PET image-based parameters in oesophageal cancer and impact of tumour delineation methodology.
Hatt M; Visvikis D; Albarghach NM; Tixier F; Pradier O; Cheze-le Rest C
Eur J Nucl Med Mol Imaging; 2011 Jul; 38(7):1191-202. PubMed ID: 21365252
[TBL] [Abstract][Full Text] [Related]
8. Lesion-based detection of early chemosensitivity using serial static FDG PET/CT in metastatic colorectal cancer.
Buvat I; Necib H; Garcia C; Wagner A; Vanderlinden B; Emonts P; Hendlisz A; Flamen P
Eur J Nucl Med Mol Imaging; 2012 Oct; 39(10):1628-34. PubMed ID: 22710958
[TBL] [Abstract][Full Text] [Related]
9. FDG PET/CT in Crohn's disease: correlation of quantitative FDG PET/CT parameters with clinical and endoscopic surrogate markers of disease activity.
Saboury B; Salavati A; Brothers A; Basu S; Kwee TC; Lam MG; Hustinx R; Louis E; Torigian DA; Alavi A
Eur J Nucl Med Mol Imaging; 2014 Apr; 41(4):605-14. PubMed ID: 24253895
[TBL] [Abstract][Full Text] [Related]
10. Repeatability of metabolically active tumor volume measurements with FDG PET/CT in advanced gastrointestinal malignancies: a multicenter study.
Frings V; van Velden FH; Velasquez LM; Hayes W; van de Ven PM; Hoekstra OS; Boellaard R
Radiology; 2014 Nov; 273(2):539-48. PubMed ID: 24865311
[TBL] [Abstract][Full Text] [Related]
11. Intra-tumour 18F-FDG uptake heterogeneity decreases the reliability on target volume definition with positron emission tomography/computed tomography imaging.
Dong X; Wu P; Sun X; Li W; Wan H; Yu J; Xing L
J Med Imaging Radiat Oncol; 2015 Jun; 59(3):338-45. PubMed ID: 25708154
[TBL] [Abstract][Full Text] [Related]
12. Early Metabolic Response to Neoadjuvant Treatment: FDG PET/CT Criteria according to Breast Cancer Subtype.
Groheux D; Majdoub M; Sanna A; de Cremoux P; Hindié E; Giacchetti S; Martineau A; de Roquancourt A; Merlet P; Visvikis D; Resche-Rigon M; Hatt M; Espié M
Radiology; 2015 Nov; 277(2):358-71. PubMed ID: 25915099
[TBL] [Abstract][Full Text] [Related]
13. Repeatability of 18F-FDG PET/CT in Advanced Non-Small Cell Lung Cancer: Prospective Assessment in 2 Multicenter Trials.
Weber WA; Gatsonis CA; Mozley PD; Hanna LG; Shields AF; Aberle DR; Govindan R; Torigian DA; Karp JS; Yu JQ; Subramaniam RM; Halvorsen RA; Siegel BA; ;
J Nucl Med; 2015 Aug; 56(8):1137-43. PubMed ID: 25908829
[TBL] [Abstract][Full Text] [Related]
14. Validation of several SUV-based parameters derived from 18F-FDG PET for prediction of survival after SIRT of hepatic metastases from colorectal cancer.
Fendler WP; Philippe Tiega DB; Ilhan H; Paprottka PM; Heinemann V; Jakobs TF; Bartenstein P; Hacker M; Haug AR
J Nucl Med; 2013 Aug; 54(8):1202-8. PubMed ID: 23729697
[TBL] [Abstract][Full Text] [Related]
15. The role of routine clinical pretreatment 18F-FDG PET/CT in predicting outcome of colorectal liver metastasis.
Tam HH; Cook GJ; Chau I; Drake B; Zerizer I; Du Y; Cunningham D; Koh DM; Chua SS
Clin Nucl Med; 2015 May; 40(5):e259-64. PubMed ID: 25742225
[TBL] [Abstract][Full Text] [Related]
16. Serial assessment of FDG-PET FDG uptake and functional volume during radiotherapy (RT) in patients with non-small cell lung cancer (NSCLC).
Edet-Sanson A; Dubray B; Doyeux K; Back A; Hapdey S; Modzelewski R; Bohn P; Gardin I; Vera P
Radiother Oncol; 2012 Feb; 102(2):251-7. PubMed ID: 21885145
[TBL] [Abstract][Full Text] [Related]
17. Prognostic Value of Total Lesion Glycolysis Measured by 18F-FDG-PET/CT in Patients with Colorectal Cancer.
Ogawa S; Itabashi M; Kondo C; Momose M; Sakai S; Kameoka S
Anticancer Res; 2015 Jun; 35(6):3495-500. PubMed ID: 26026116
[TBL] [Abstract][Full Text] [Related]
18. The role of sequential 18(F) -FDG PET/CT in predicting tumour response after preoperative chemoradiation for rectal cancer.
Sun W; Xu J; Hu W; Zhang Z; Shen W
Colorectal Dis; 2013 May; 15(5):e231-8. PubMed ID: 23384167
[TBL] [Abstract][Full Text] [Related]
19. The role of early ¹⁸F-FDG PET/CT in prediction of progression-free survival after ⁹⁰Y radioembolization: comparison with RECIST and tumour density criteria.
Zerizer I; Al-Nahhas A; Towey D; Tait P; Ariff B; Wasan H; Hatice G; Habib N; Barwick T
Eur J Nucl Med Mol Imaging; 2012 Sep; 39(9):1391-9. PubMed ID: 22644713
[TBL] [Abstract][Full Text] [Related]
20. Baseline ¹⁸F-FDG PET image-derived parameters for therapy response prediction in oesophageal cancer.
Hatt M; Visvikis D; Pradier O; Cheze-le Rest C
Eur J Nucl Med Mol Imaging; 2011 Sep; 38(9):1595-606. PubMed ID: 21559979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
